Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Badman PD"'
Autor:
R. C. Coombes, P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, N. Rosenfeld, J. Garcia-Corbacho, N. Cresti, R. Plummer, A. Armstrong, R. Allerton, D. Landers, H. Nicholas, L. McLellan, A. Lim, F. Mouliere, O. E. Pardo, V. Ferguson, M. J. Seckl
Publikováno v:
Nature Communications, 13(1):3246. Nature Publishing Group UK
Coombes, R C, Badman, P D, Lozano-Kuehne, J P, Liu, X, Macpherson, I R, Zubairi, I, Baird, R D, Rosenfeld, N, Garcia-Corbacho, J, Cresti, N, Plummer, R, Armstrong, A, Allerton, R, Landers, D, Nicholas, H, McLellan, L, Lim, A, Mouliere, F, Pardo, O E & Seckl, M J 2022, ' Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer ', Nature Communications, vol. 13, no. 1, 3246 . https://doi.org/10.1038/s41467-022-30666-0, https://doi.org/10.1038/s41467-022-30666-0
Coombes, R C, Badman, P D, Lozano-Kuehne, J P, Liu, X, Macpherson, I R, Zubairi, I, Baird, R D, Rosenfeld, N, Garcia-Corbacho, J, Cresti, N, Plummer, R, Armstrong, A, Allerton, R, Landers, D, Nicholas, H, McLellan, L, Lim, A, Mouliere, F, Pardo, O E & Seckl, M J 2022, ' Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer ', Nature Communications, vol. 13, no. 1, 3246 . https://doi.org/10.1038/s41467-022-30666-0, https://doi.org/10.1038/s41467-022-30666-0
We conducted a phase IIa, multi-centre, open label, single arm study (RADICAL; NCT01791985) of AZD4547 (a potent and selective inhibitor of Fibroblast Growth Factor Receptor (FGFR)-1, 2 and 3 receptor tyrosine kinases) administered with anastrozole o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf41360879c66a88fb3325689e8e6361
Autor:
Coombes RC; Department of Surgery and Cancer, Imperial College London, London, UK. c.coombes@imperial.ac.uk., Badman PD; Department of Surgery and Cancer, Imperial College London, London, UK., Lozano-Kuehne JP; Department of Surgery and Cancer, Imperial College London, London, UK., Liu X; Department of Surgery and Cancer, Imperial College London, London, UK., Macpherson IR; Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK., Zubairi I; Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK., Baird RD; Medical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK., Rosenfeld N; Medical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK., Garcia-Corbacho J; Medical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK., Cresti N; Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK., Plummer R; Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK., Armstrong A; Breast Research Office, The Christie NHS Foundation Trust, Christie Hospital, Manchester, UK., Allerton R; C8 Admin Offices, Russell's Hall Hospital, Russells Hall, UK., Landers D; Astrazeneca, Cheshire, UK., Nicholas H; Department of Surgery and Cancer, Imperial College London, London, UK., McLellan L; ECMC Programme Office, Research and Innovation, Cancer Research UK, London, UK., Lim A; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK., Mouliere F; Medical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK.; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Centre Amsterdam, Amsterdam, The Netherlands., Pardo OE; Department of Surgery and Cancer, Imperial College London, London, UK., Ferguson V; Department of Surgery and Cancer, Imperial College London, London, UK., Seckl MJ; Department of Surgery and Cancer, Imperial College London, London, UK. m.seckl@imperial.ac.uk.
Publikováno v:
Nature communications [Nat Commun] 2023 Jan 17; Vol. 14 (1), pp. 260. Date of Electronic Publication: 2023 Jan 17.
Autor:
Coombes RC; Department of Surgery and Cancer, Imperial College London, London, UK. c.coombes@imperial.ac.uk., Badman PD; Department of Surgery and Cancer, Imperial College London, London, UK., Lozano-Kuehne JP; Department of Surgery and Cancer, Imperial College London, London, UK., Liu X; Department of Surgery and Cancer, Imperial College London, London, UK., Macpherson IR; Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK., Zubairi I; Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK., Baird RD; Medical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK., Rosenfeld N; Medical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK., Garcia-Corbacho J; Medical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK., Cresti N; Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK., Plummer R; Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK., Armstrong A; Breast Research Office, The Christie NHS Foundation Trust, Christie Hospital, Manchester, UK., Allerton R; C8 Admin Offices, Russell's Hall Hospital, Russells Hall, UK., Landers D; Astrazeneca, Cheshire, UK., Nicholas H; Department of Surgery and Cancer, Imperial College London, London, UK., McLellan L; ECMC Programme Office, Research and Innovation, Cancer Research UK, London, UK., Lim A; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK., Mouliere F; Medical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK.; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Centre Amsterdam, Amsterdam, The Netherlands., Pardo OE; Department of Surgery and Cancer, Imperial College London, London, UK., Ferguson V; Department of Surgery and Cancer, Imperial College London, London, UK., Seckl MJ; Department of Surgery and Cancer, Imperial College London, London, UK. m.seckl@imperial.ac.uk.
Publikováno v:
Nature communications [Nat Commun] 2022 Jun 10; Vol. 13 (1), pp. 3246. Date of Electronic Publication: 2022 Jun 10.